The importance of the presenilin/ γ-secretase complex has vastly surpassed its initial identity as the enzyme that generates the amyloid-β protein, an aberrant form of which is implicated in Alzheimer's disease (AD). This conserved and omnipresent membrane protein complex is required for life in all multicellular animals. Its roster of client substrates is large and growing and includes some of the most interesting and widely studied protein families in biology. Despite intense study for more than a decade, much still needs to be learned about presenilin in health and disease.
The discovery of presenilins as ubiquitous intramembrane proteases in metazoans exemplifies an emerging trend in biology. The traditional distinction between basic and applied research is becoming increasingly blurred, as studies initiated with a strictly disease-oriented focus uncover fundamental biological mechanisms. In the example of presenilin, the quest for genetic causes of AD led to linkage analysis and positional cloning that identified a new human gene (originally called S182) (Sherrington et al., 1995) , mutations in which produce the most severe form of dominantly inherited AD. Although the function of this polytopic membrane protein could not be predicted from its primary structure, it was soon shown to be the first intramembrane aspartyl protease (Wolfe et al., 1999) . This knowledge emerged around the time that site 2 protease (S2P) was identified as a metalloprotease that cleaves sterol regulatory element binding protein within the Golgi membrane as part of cholesterol homeostasis (Brown et al., 2000) . These discoveries established the existence of intramembrane cleaving proteases (I-CLiPs) (reviewed in Wolfe and Kopan, 2004) and led to the recognition of a hitherto unknown signaling mechanism in cells dubbed regulated intramembrane proteolysis or RIP (Brown et al., 2000) .
The identification of presenilin 1 (PS1, a.k.a. S182) and presenilin 2 (PS2) in humans was followed shortly by the realization that the Caenorhabditis elegans homolog (Sel-12) played a necessary role in Notch signaling, specifically in the release of the Notch intracellular domain (NICD) from its transmembrane precursor. Subsequent studies in worms, flies, and mammals established presenilin as the active site of a four-protein complex (γ-secretase) that cleaves many type 1 membrane proteins within the lipid bilayer at two or more bonds (reviewed in Kopan and Ilagan, 2004 ) (see Figure 1 ). Missense mutations in PS1 or PS2 (more than 160 are now known) cause a subtle but ultimately lethal shift in the cleavage of the transmembrane domain of amyloid precursor protein (APP). This results in an increase in the ratio of the 42-to 40-residue amyloid-β protein (Aβ), leading to Aβ aggregation and AD.
Presenilin and Its Partners
The findings that γ-secretase activity could be dramatically reduced by either presenilin deficiency or transition-state analogs for aspartyl proteases together suggested that presenilin might be a new aspartyl protease with a membrane-embedded active site. Sequence alignments showed two aspartates that are predicted to reside in adjacent transmembrane domains and are completely conserved in metazoans. Mutation of either of these aspartates dramatically reduced γ-secretase activity, suggesting that they serve as the active site (Wolfe et al., 1999) . Presenilins are cleaved into two stable pieces, an N-terminal fragment (NTF) and a C-terminal fragment (CTF), that remain associated as a heterodimer. This heterodimer is tightly regulated by limiting cellular factors and becomes associated with large complexes (Kopan and Ilagan, 2004) . All of this suggested that γ-secretase is a multiprotein complex, with the PS heterodimer as its catalytic component and the cofactors titrating the levels of active protease in a cell. Consistent with this view, the interface between the NTF and CTF of PS1 is the molecular target of transition-state analog inhibitors of γ-secretase, suggesting that the active site resides at this interface, with each presenilin subunit contributing one of the catalytic aspartates.
The presenilin-containing γ-secretase complex is an unusual membrane-embedded protease that processes a wide variety of integral membrane proteins, clearing protein stubs from the lipid bilayer and participating in critical signaling pathways. The protease is also central to Alzheimer's disease and certain cancers and is therefore an important therapeutic target. Here we highlight recent progress in deciphering the role of presenilin/γ-secretase in biology and medicine and pose key questions for future study.
Identifying the limiting cofactors of γ-secretase and reconstituting the proteolytic complex in cells solidified presenilin's role as the catalytic component. Coimmunoprecipitation experiments with presenilin led to the discovery of Nicastrin, a single pass membrane protein, as a required component of the complex. Meanwhile, genetic screens in C. elegans identified the multipass membrane proteins Aph-1 and Pen-2 also as essential components of the complex (reviewed in De Strooper, 2003) . Overexpression of all four components (presenilin, Nicastrin, Aph-1, and Pen-2; see Figure 1 ) resulted in elevated γ-secretase activity. Coexpression in the budding yeast Saccharomyces cerevisiae is especially compelling: this organism does not possess γ-secretase activity, nor does it encode any of these four proteins. Purification of γ-secretase to virtual homogeneity (Fraering et al., 2004) revealed just these four proteins, indicating that they are both necessary and sufficient for protease activity.
Nevertheless, recent work suggests that other proteins may interact with the complex and regulate its function. At least two proteins have been reported as potential modulatory subunits: CD147 and TMP21. The type I membrane glycoprotein CD147 copurified with γ-secretase from human cell lines; reduction of CD147 using RNA interference (RNAi) increased Aβ production, suggesting that CD147 downregulates Aβ (Zhou et al., 2005) . The cargo protein TMP21 was reported to differentially regulate the Aβ-producing midtransmembrane γ cleavage without affecting the ε cleavage closer to the membrane-cytosol interface, which releases the APP intracellular domain (AICD) into the cytosol (Chen et al., 2006 ) (see Figure 1) . Knockdown of TMP21 increased 40-and 42-residue Aβ production without altering AICD levels. However, cleavage of APP substrate should necessarily produce equimolar amounts of AICD and Aβ, as has been clearly established (Kakuda et al., 2006) . In addition, the retrieval receptor Rer1p was recently reported to bind to immature Nicastrin and compete with Aph-1. In this way, Rer1p could regulate γ-secretase assembly in the endoplasmic reticulum (ER) and early Golgi (Spasic et al., 2007) . In contrast, another report showed Rer1 interacting with unassembled Pen2 (Kaether et al., 2007) . These initial reports require confirmation, but the study of proteins that interact with and modulate γ-secretase is a fertile field for the future and may reveal new therapeutic targets.
The biochemical roles of the various components of the γ-secretase complex are only partially understood. Presenilin contains a docking site (Kornilova et al., 2005) where the transmembrane domain of the substrate interacts prior to its entry into the internal active site, which should contain water and the two catalytic aspartates. Nicastrin plays a role in substrate recognition: its ectodomain resembles an aminopeptidase but lacking key catalytic residues, and (Top) The γ-secretase complex is comprised of the integral membrane proteins presenilin (as NTF and CTF subunits; orange and yellow, respectively), nicastrin (bright green), Aph-1 (blue), and Pen-2 (red), with the active site inside presenilin at the NTF-CTF interface. Membrane protein stubs serving as substrates (pale green) dock both on the outer surface of presenilin at the NTF-CTF interface and with the nicastrin ectodomain before entering into the internal active site.
(Middle left) Proteolysis by γ-secretase is involved in certain cell-signaling events (and other functions such as adhesion). After ectodomain shedding, typically by a membranetethered metalloprotease, the substrate is cleaved by γ-secretase to release an intracellular domain that triggers transcriptional regulation.
(Middle right) Proteolysis by γ-secretase is involved in membrane protein turnover. Removal of protein stubs from the membrane by γ-secretase is followed by further degradation (e.g., by the proteasome). this domain can interact with the N terminus of γ-secretase substrates (Shah et al., 2005 ) (see Figure 1 ). The shedding of the substrate's ectodomain (e.g., by either α-or β-secretase in the case of APP) thus allows the free N terminus of the membraneretained stub to interact with Nicastrin. Aph-1 is thought to function as a scaffold for the γ-secretase complex, assembling first with Nicastrin and then with presenilin and Pen-2. Pen-2 serves as a trigger for endoproteolysis of the presenilin holoprotein into the active heterodimer, although it is independently required for γ-secretase activity as well. There are at least three variants of Aph-1 in mammalian cells, but cellular expression of either PS1 or PS2 with each of these variants (plus Nicastrin and Pen-2) yielded six different complexes that produced similar cleavage patterns with APP . Studies with knockout mice have established some differential effects of the two presenilin variants and also of the Aph-1 isoforms (for example, see Serneels et al., 2005) , perhaps due to varying tissue expression. Moreover, these complexes may be differentially localized within cells, where they could have distinct proteolytic functions. Such questions now need to be resolved.
Toward Elucidation of Structure
Defining the structure of the protease complex is another major focus of ongoing work. Cysteine mutagenesis coupled with crosslinking to chemical probes suggests the existence of a hydrophilic pore leading from the luminal/extracellular milieu to the catalytic aspartates; this method has also suggested specific sites for binding of inhibitors (Sato et al., 2006a; . The size and stoichiometry of the γ-secretase complex, critical to the elucidation of its structure, has been a matter of controversy, with estimates ranging from ?150 KDa to ?2 MDa. Although some studies suggested that the complex contains two PS molecules at its catalytic core (for example, see Schroeter et al., 2003) and that the putative PS homolog, signal peptide peptidase (SPP), likewise can form a dimer, more recent findings reveal that only one PS molecule per complex is sufficient for γ-secretase activity and that monomeric SPP is proteolytically active (Narayanan et al., 2007) .
Purification of γ-secretase has allowed single particle analysis by electron microscopy (EM) to provide the first images of the protease (Lazarov et al., 2006) . Although the resolution was low (?15 Å), certain structural features could be gleaned, including an interior chamber reminiscent of the proteasome and two openings facing the luminal and cytoplasmic sides that could provide entry of water molecules and exit ports for the two proteolytic products. A second EM structural study reported images at ?55 Å resolution (Ogura et al., 2006) , making structural interpretation difficult. Ongoing studies using cryo-EM and/or 2D crystallization may provide higher resolution, yielding better clues to the catalytic mechanism, substrate interactions, and inhibitor binding. Three-dimensional crystallization of the entire complex, with its minimum of 19 transmembrane domains, will present a particular challenge and should be preceded by the crystallization of PS homologs like SPP that can act alone.
Many Presenilin Substrates
While APP was the first substrate of γ-secretase to be recognized, it is now apparent that this protease evolved to cleave Notch and several other functionally critical type 1 membrane glycoproteins (Kopan and Ilagan, 2004) . Although the number of reported substrates already exceeds three dozen, unbiased proteomic searches may uncover many more. There is extensive evidence that PS/γ-secretase cannot efficiently cleave full-length type 1 proteins; most of the ectodomain must first be removed (generally by metalloproteases such as ADAM-10 or -17) to enable intramembrane cleavage of the remaining stub. Shedding of the large ectodomain may remove steric hindrance to the γ cleavage and may also allow subtle relaxation of the transmembrane α helix to enable access of the catalytic aspartates to the amide bonds fated for cleavage. Whether most or all type 1 membrane proteins that undergo ectodomain shedding become γ-secretase substrates remains to be seen.
The known substrates have many diverse functions, including cell fate determination (Notch and Jagged), cell-cell adhesion (N-and E-cadherins, CD44, and Nectin-1α), regulation of ion conductance (β2 subunit of the voltage-gated sodium channel), growth factor-dependent receptor tyrosine kinase signaling (ErbB4), and neurotrophin signaling (p75 NTR). Although the early implication of Notch as a vital substrate raised the possibility that most or all substrates underwent γ-secretase cleavage to release signaling fragments to the nucleus, this may not be a unifying characteristic of the substrates. For example, γ-secretase cleavage of E-cadherin releases its bound protein partners, α-and β-catenin, from the actin cytoskeleton, thus contributing to adherens junction disassembly; but the E-cadherin intracellular domain (ICD) is not known to be a nuclear signaling molecule. In the case of APP, several laboratories have reported that the APP ICD can regulate gene transcription, with each laboratory identifying a different nuclear target. But none of these findings was replicated when presenilins were genetically or pharmacologically inactivated or APP and its homologs were deleted in cells or mice (Hebert et al., 2006) . At this juncture, nuclear signaling roles for the ICDs of APP and several other γ-secretase substrates are not established, and RIP appears capable of conferring other functions.
Such considerations suggest that the PS/γ-secretase complex evolved principally as an efficient mechanism to clear out the membrane-embedded domains of many different type 1 proteins, a function that has earned this complex the name proteasome of the membrane (Kopan and Ilagan, 2004; Small, 2002) . If so, some of the many released ICDs may have been stable enough in the cytoplasm to acquire various physiological functions (e.g., nuclear signaling), whereas others were extremely labile and essentially without activity (see Figure 1) . SPP could perform the same general function for certain type 2 membrane proteins. A question for future research is whether new types of I-CLiPs will be discovered that turn over the transmembrane domains of polytopic proteins.
Nonproteolytic Functions of Presenilin
A few studies have suggested that PS can also mediate functions that are independent of its proteolytic activity. Not all attempts to show this phenomenon have incorporated a "proteolytically dead" PS molecule having its active site asparates mutated (e.g., PS1 D257A). One that has is the report that mouse embryonic fibroblasts cultured from PS1/2 double knockout mice have increased calcium ion concentrations in the ER and that this phenotype can be rescued equally by transfecting wild-type or D257A PS1 constructs (Tu et al., 2006) . The authors propose that the PS holoprotein forms ER calcium ion leak channels and that the D257A mutant, which does not undergo endoproteolysis, can function in this way. Other reports have suggested that PS1 participates in the regulation of intracellular protein trafficking independently of its proteolytic activity (most recently, Wang et al., 2006) , although proteolytically inactive mutants could cause saturation of internalization pathways due to massive accumulation of uncleaved γ-secretase substrates. Some studies claiming a trafficking or other nonproteolytic function of PS did not examine D257A PS constructs. Moreover, the mechanisms of the observed changes are unclear, and one cannot yet exclude indirect effects secondary to PS-mediated substrate cleavage. Additional studies are now needed to unequivocally confirm nonproteolytic PS functions.
Evolutionary Implications
Presenilin and the γ-secretase complex are highly conserved in metazoans, in which the protease is essential for differentiation and development due to its role in Notch signaling.
Genetic alterations in γ-secretase components that reduce or eliminate proteolytic function lead to developmental abnormalities similar to those seen with Notch deficiency. Thus, coevolution of the PS complex members and the Notch pathway was likely to be a key phase that made the emergence of multicellular animals possible. Presenilin's acquisition of partner proteins that are essential for proteolytic activity suggests that the enzyme requires tight regulation. The development of such regulation likely coincided with the emergence of the Notch pathway as a powerful mechanism for controlling cell differentiation.
Distant presenilin homologs have been discovered, and one of these, SPP, apparently functions as a protease on its own without the need for protein partners (Weihofen et al., 2003) . SPP and SPP-like proteases are found in unicellular organisms as well, suggesting that intramembrane aspartyl protease catalysis is ancient. As its name implies, the major role of SPP is to clear out remnant signal peptides left behind in the ER membrane after their release by signal peptidase, suggesting that the biological function of ur-presenilins was to help remove proteins from the membrane. Over time, the presenilin-generated cleavage products of certain proteins may have evolved new functions, such as cell signaling. γ-Secretase retains this general clearing function in addition to its putatively more recently acquired functions such as Notch and Erb-B4 signaling. Likewise, certain products generated by SPP have acquired biological functions, such as in immune surveillance in mammals.
One of the SPP-like proteases, SPPL2b, was recently found to cleave tumor necrosis factor α in cells (Fluhrer et al., 2006) , and the released intracellular domain can stimulate IL-12 production in activated dendritic cells . Examination of the products generated by SPPL2b revealed a double cleavage of the substrate, similar to that by γ-secretase. Another polytopic membrane aspartyl protease family, the type IV prepilin proteases (TFPPs), possesses PS-like sequence motifs that contain the catalytic aspartates (Steiner et al., 2000) ; however, the aspartate dyad of TFPP apparently lies outside the membrane, and these proteases do not seem evolutionarily related to PS and SPP.
PS/γ-secretase and the SPP family exhibit key differences. First, PS requires three different membrane protein cofactors for proteolytic function, whereas the SPPs can carry out proteolysis on their own (Narayanan et al., 2007; Weihofen et al., 2003) . Second, PS and SPP are oriented oppositely in the membrane (Friedmann et al., 2004; Laudon et al., 2005; Nyborg et al., 2004) . This flipped topology is consistent with the third difference, that PS/γ-secretase cuts type I integral membrane proteins (oriented N to C terminus from the lumenal/extracellular space to the cytosol), whereas the SPPs cleave type II integral membrane proteins (oriented C to N terminus) (Weihofen et al., 2003) . Notwithstanding these important differences, PS/γ-secretase and SPP display biochemical and pharmacological similarities. Upon solubilization from the asymmetric environment of the lipid bilayer, the two proteases can cleave the same substrates (Sato et al., 2006b ). This finding suggests that the two proteases, with their conserved aspartate motifs, have similar active sites, a concept supported by the fact that certain transition-state analogs can inhibit both proteolytic activities (Weihofen et al., 2003) . Other small organic molecules, including helical peptide-type docking site inhibitors, block the activities of both proteases, implying common binding sites for these agents as well (Sato et al., 2006b; Weihofen et al., 2003) .
The intramembrane aspartyl protease family could have served a role in membrane protein extrusion prior to acquiring transmembrane residues that allow proteolysis. Such a function would require a means of lateral entry of transmembrane domains prior to extrusion. Indeed, SPP is critical for dislocating the class I major histocompatibility complex (MHC) from the membrane during infection by human cytomegalovirus (Loureiro et al., 2006) , allowing the virus to evade detection by the immune system. Whether the proteolytic function of SPP is required for MHC dislocation is unknown, although MHC is extruded as a full-length protein (i.e., without intramembrane proteolysis). Another possibility is that the intramembrane aspartyl proteases were originally channel proteins, an idea supported by the aforementioned finding that PS holoprotein can apparently serve as an ER calcium leak channel independent of its role in γ-secretase (Tu et al., 2006 ). Presenilin's ability to serve as a calcium channel may be vestigial, a biochemical relic of an ancient function acquired prior to the acquisition of the intramembrane aspartates.
PS/γ-Secretase in AD Pathogenesis and Treatment
The identification of presenilin as the catalytic component of γ-secretase provides a linchpin for the amyloid (Aβ) hypothesis of AD: all of the mutations currently known to cause autosomal dominant AD occur either in the substrate (APP) or the protease (presenilin) of the reaction that produces Aß. Nevertheless, it has been suggested that the clinical PS1 and PS2 mutations confer the disease phenotype principally through mechanisms other than promoting Aβ42 accumulation. This idea is often coupled with a discussion of whether the AD-causing mutations represent a gain or loss of presenilin function. One line of reasoning begins with the observation that conditional PS knockout mice develop neurodegeneration and deficits in cognition reminiscent of key features of AD (Shen and Kelleher, 2007) . Thus, it is argued, presenilin loss of function confers an AD-like state. But there are three key misunderstandings here. First, many genetic alterations in mice can produce neuronal loss and impaired cognition, and these nonspecific phenotypes also occur in various human disorders of diverse etiology. Second, any mouse phenotype that lacks Aβ accumulation (as PS knockouts do) cannot be thought of as a model for AD, as the human disease is defined by the invariant accumulation of Aβ. Third, if PS mutations in familial AD conferred a clinically important loss of neural function independent of their elevation of Aβ42/40 ratios, then the detailed clinical and neuropathological phenotypes of the carriers would be expected to be different in part from those with APP mutations, but the phenotypes are generally indistinguishable (i.e., typical AD).
As to whether clinical PS mutations confer gain or loss of function, this simple dichotomy has been used to describe the effects of mutations in newly discovered genes during development, often in invertebrates. But once the specific biochemical activity of a gene product is well understood, mutations may be found to confer neither loss nor gain of function exclusively but some of both. Many PS mutations cause less γ-secretase cleavage of APP at the Aβ40-41 peptide bond relative to cleavage at the Aβ42-43 bond, thus conferring both "loss" and "gain" of proteolytic activity, depending on the bond in question. Even if one views the clinical PS mutations as conferring an overall loss of proteolytic function, the outcome for the organism is the gain of a toxic product, i.e, more synaptotoxic Aβ.
Recently, a reconciliation of the seemingly antithetic views of "loss" and "gain" of function has been proposed (De Strooper, 2007; Wolfe, 2007) . Key to this unifying idea is the finding that γ-secretase apparently cuts at the ε site first, to produce either a 48-or 49-residue Aβ (Kakuda et al., 2006; Wolfe, 2007) . Subsequent cuts every 3-4 residues (i.e., every helical turn of the substrate) ultimately produce the 39-43 residue Aβ peptides that are secreted from the cell. Familial AD mutations in PS typically reduce the catalytic efficiency of γ-secretase, having the net result that while less Aβ may be produced, a larger proportion will be longer Aβ peptides such as Aβ42. Thus, a loss of function (reduced proteolytic activity) could lead to a gain of function (increased Aβ42/40 ratio).
In short, focusing on gain or loss of function is too simple to be useful once one knows the specific biochemical activity (in this case, endoproteolysis) that a gene product confers. Instead, we need to decipher at the atomic level exactly how a PS missense mutation alters the conformation of the active site to shift its cleavage specificity. And arguing that the clinical PS mutations may cause AD by perturbing the processing of other PS substrates (e.g., Notch) ignores the key observation that mutations in just a single PS substrate (APP), but in no others, produce AD having a clinicopathological phenotype indistinguishable from that of the PS mutations themselves. Parsimony supports a common effect of both PS and APP mutations: to increase brain Aβ42 levels and thus enhance the formation of synapse-impairing oligomers. It is also important to recall that in the overwhelming majority of AD patients, PS is wild-type, and factors unrelated to alteration of Aβ42 production by γ-secretase are at fault.
As to its attractiveness as a therapeutic target, presenilin is often viewed adversely because of its vital function in cleaving Notch and other important substrates. But there is now good evidence that small molecules can be found that have large therapeutic indices-i.e., they bind to the γ complex in a way that inhibits the cleavage of Notch far less than that of APP. Such "modulators" of γ-secretase include certain nonsteroidal antiinflammatory drugs (NSAIDs) that apparently shift cleavage specificity from Aβ42 by one turn down the transmembrane helix to Aβ38 (Weggen et al., 2001 ). These compounds are therapeutically attractive, assuming they otherwise have salutary pharmacological properties. One "smart γ-secretase inhibitor" of this type, R-flurbiprofen (which no longer inhibits cyclooxygenase), is already in late-stage human trials.
Other γ-secretase modulators include compounds identified from kinase inhibitor collections. These compounds do not shift where γ-secretase cuts APP; rather, they block Aβ production altogether without inhibiting Notch proteolysis. The discovery of such agents emerged from the finding that ATP and other nucleotides can stimulate Aβ production (Netzer et al., 2003) , even in purified γ-secretase preparations (Fraering et al., 2005) , suggesting a nucleotide binding site on the enzyme complex and/or the APP substrate that serves to allosterically regulate substrate selectivity. As with the NSAIDs, however, more work is needed to improve the potency of these modulators and to better establish their biochemical mechanism of action.
γ-Secretase As a Target for Cancer
That PS/γ-secretase is required for Notch signaling is considered an obstacle in developing inhibitors as AD therapeutics. However, this potential problem should be an advantage for chemotherapy of certain cancers. The critical function of Notch in differentiation, in particular to maintain precursor cell niches, can go awry, with excess stimulation of Notch signaling causing overproliferation of these immature precursors. The developmental pathways Hedgehog and Wnt are considered important targets for cancer chemotherapy for similar reasons.
Excessive Notch signaling has been implicated in several types of neoplastic diseases (Shih Ie and Wang, 2007) . A chromosomal translocation that results in a truncated, constitutively active form of Notch1 is found in 10% of human T cell acute lymphoblastic leukemia (T-ALL) cases, and activating point mutations in Notch1 have been found recently in ?50% of all T-ALL. Elevation of Notch3 expression is implicated in subsets of nonsmall cell lung cancer and ovarian cancer, and activation of Notch signaling is also implicated in breast cancer. γ-secretase inhibitors can block proliferation of Notch-dependent tumor cell lines and reduce tumor growth in mouse models, and one inhibitor has entered phase I clinical trials for T-ALL and breast cancer. Notch signaling also plays an important role in angiogenesis and may be critical for self-renewal of cancer stem cells; inhibiting these Notch functions is considered a worthy anticancer strategy.
In spite of this promise, the same caveats about the use of γ-secretase inhibitors in AD apply here. Blocking Notch signaling too much and for too long may lead to unacceptable toxic effects, such as gastrointestinal dysfunction and immunosuppression. The hope is that a therapeutic window exists, especially if certain types of cancer cells are overly dependent on Notch signaling for survival. A further hope is that γ-secretase inhibitors could be given for shorter periods of time and in smaller doses, in combination with other antineoplastic agents. Such regimens may avoid complications of chronically blocking γ-secretase processing of substrates.
The Future: Questions Abound Despite a growing understanding of presenilin biology, there are at least six key questions that remain to be answered. How does presenilin select among so many competitive substrates? How are protein substrates translocated into its active site? Precisely how does PS carry out hydrolysis of peptide bonds within a hydrophobic environment? Does the lipid composition of membranes strongly regulate substrate selection and cleavage specificity? Does presenilin function differently in different cell types and at distinct subcellular loci? And how do pharmacological modulators subtly alter Aβ production? There is reason to be cautiously optimistic that pharmacological modulation of PS/γ-secretase activity will become a viable therapeutic approach for AD and possibly for cancers as well. Given the remarkably wide range of substrates and biological roles of γ-secretase discovered so far, other therapeutic applications may ultimately be revealed.
